<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Rapid cycling bipolar disorder in adults: Treatment of major depression
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Rapid cycling bipolar disorder in adults: Treatment of major depression
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Rapid cycling bipolar disorder in adults: Treatment of major depression
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ralph Kupka, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Keck, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H92693288">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bipolar disorder is characterized by mood episodes that are nearly always recurrent [
         <a href="#rid1">
          1,2
         </a>
         ]. Patients who experience at least four episodes during a 12-month period are classified as “rapid cycling” [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The term was first used in 1974 to describe patients with bipolar disorder who were unresponsive to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         [
         <a href="#rid3">
          3
         </a>
         ]. However, it is now clear that any form of pharmacotherapy is typically less beneficial for rapid cycling bipolar disorder than non-rapid cycling bipolar disorder [
         <a href="#rid4">
          4
         </a>
         ]. In addition, lithium is not less effective than other drugs in rapid cycling [
         <a href="#rid5">
          5
         </a>
         ], and may perhaps be as effective in rapid-cycling and non-rapid cycling bipolar patients [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         This topic reviews the treatment of major depression in rapid cycling patients. The treatment of mania and hypomania in rapid cycling patients, and the epidemiology, pathogenesis, clinical features, and diagnosis of rapid cycling in patients with bipolar disorder are discussed separately, as is the diagnosis and general treatment of bipolar disorder:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16847.html" rel="external">
          "Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15249.html" rel="external">
          "Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15267.html" rel="external">
          "Bipolar major depression in adults: Choosing treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H92693295">
         <span class="h1">
          DEFINITION OF RAPID CYCLING BIPOLAR DISORDER
         </span>
         <span class="headingEndMark">
          —
         </span>
         According to the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), bipolar disorder is characterized by episodes of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ), hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. The major subtypes of bipolar disorder include bipolar I and bipolar II. Patients with bipolar I disorder experience manic, and nearly always experience major depressive and hypomanic episodes. Bipolar II disorder is marked by at least one hypomanic episode, at least one major depressive episode, and the absence of manic episodes. Additional information about the clinical features and diagnosis of bipolar disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14642.html" rel="external">
          "Bipolar disorder in adults: Clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Rapid cycling specifies a particular course of illness that can occur in bipolar I disorder or bipolar II disorder, rather than a subtype of bipolar disorder [
         <a href="#rid2">
          2
         </a>
         ]. The diagnostic criteria for rapid cycling are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least four mood episodes in the previous 12 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The episodes meet both the symptom and duration criteria for a manic, hypomanic, or major depressive episode. Although the symptoms that occur as part of a rapid cycling pattern are no different from symptoms that occur as part of a non-rapid cycling pattern, rapid cycling episodes are typically of shorter duration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The episodes are demarcated by a period of partial or full remission for at least two months, or by a switch to an episode of opposite polarity. Manic and hypomanic episodes are counted as being on the same pole; thus, a switch in polarity involves one of these episodes and an episode of major depression.
        </p>
        <p>
        </p>
        <p>
         Additional information about the clinical features and diagnosis of rapid cycling are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15249.html" rel="external">
          "Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H92692334">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Remission of rapid cycling mood episodes often results from the natural course of illness, rather than treatment. Thus, the primary goal of treatment is to prevent further episodes, and clinicians should attempt to prescribe medications for acute mood episodes that are also suitable for maintenance treatment.
        </p>
        <p>
         Clinicians may find that it is not feasible for rapid cycling patients to fully remit from a mood episode or avoid recurrences [
         <a href="#rid8">
          8
         </a>
         ], and that a more realistic goal is to improve functioning and reduce the frequency, intensity, and duration of mood episodes [
         <a href="#rid5">
          5
         </a>
         ]. The difficulties posed by rapid cycling usually necessitate referral to a psychiatrist.
        </p>
        <p>
         Additional information about the general principles of treating rapid cycling bipolar disorder, including the frequency of monitoring patients and the duration of a treatment trial, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16847.html" rel="external">
          "Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania", section on 'General principles'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H928771508">
         <span class="h2">
          Use of antidepressants
         </span>
         <span class="headingEndMark">
          —
         </span>
         For acute episodes of major depression that occur in patients with rapid cycling bipolar disorder, antidepressants combined with an antimanic drug may be beneficial. As an example, a meta-analysis pooled four trials that randomly assigned patients (n = 101) to either an antidepressant or a comparator (eg, placebo); the antidepressants included
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         ,
         <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">
          escitalopram
         </a>
         ,
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         [
         <a href="#rid4">
          4
         </a>
         ]. Assessments before and after treatment with the antidepressant suggested that depressive symptoms improved, and the clinical effect was large. However, heterogeneity across studies was moderate. In addition, the duration of the trials was relatively short; thus, potential worsening of the overall rapid cycling course by antidepressants could not be evaluated. Nevertheless, the investigators performed a qualitative review that suggested switching to mania was relatively high with venlafaxine.
        </p>
        <p>
         There is a broad consensus that antidepressants should generally not be used as maintenance treatment in patients with rapid cycling [
         <a href="#rid9">
          9-11
         </a>
         ]. Evidence supporting this approach includes a study of bipolar patients who were successfully treated for major depression with an antidepressant plus
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , divalproex,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and then randomly assigned to continue or discontinue the antidepressant [
         <a href="#rid12">
          12
         </a>
         ]. The mean length of follow-up was 1.7 years. In the group that continued antidepressants, the mean number of depressive episodes was greater in rapid cycling patients (n = 7) than non-rapid cycling patients (n = 23; 1.3 versus 0.4 episodes/year). By contrast, in the group that discontinued antidepressants, the rate of subsequent depressive episodes was the same in rapid cycling (n = 9) and non-rapid cycling patients (n = 28; 0.8 episodes/year).
        </p>
        <p class="headingAnchor" id="H92694034">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, response to pharmacotherapy appears to be poorer in rapid cycling bipolar disorder than non-rapid cycling bipolar disorder [
         <a href="#rid5">
          5,13-16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4240957533">
         <span class="h2">
          Overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rapid cycling bipolar patients with major depression are typically treated with pharmacotherapy. However, patients refractory to multiple medication regimens may benefit from electroconvulsive therapy (ECT).
        </p>
        <p>
         Although different drugs have been studied for treating acute episodes of rapid cycling bipolar disorder, multiple systematic reviews have concluded that the paucity of evidence from randomized trials precludes definitively determining the efficacy of specific medications [
         <a href="#rid4">
          4,7
         </a>
         ]. In addition, the natural course of illness complicates interpretation of results from relatively short-term trials.
        </p>
        <p class="headingAnchor" id="H92692341">
         <span class="h2">
          First line medication
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         as first line treatment for rapid cycling bipolar major depression based upon its efficacy and tolerability in randomized trials [
         <a href="#rid4">
          4,17-19
         </a>
         ]. In addition, other randomized trials have demonstrated that quetiapine is efficacious for the general treatment of bipolar major depression and also for maintenance treatment [
         <a href="#rid20">
          20-24
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          Quetiapine
         </a>
         is usually started at 50 mg at bedtime and titrated up by increments of 50 to 100 mg per day to achieve a target dose of 300 mg per day within four to seven days, provided that side effects do not intervene [
         <a href="#rid22">
          22
         </a>
         ]. (Doses of 600 mg per day have been studied for bipolar major depression, but provide no advantage over a dose of 300 mg per day.) The side effects  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 4
         </a>
         ) and pharmacology of quetiapine are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
         Evidence for the efficacy of
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         in rapid cycling bipolar patients with major depression includes systematic reviews of multiple studies [
         <a href="#rid4">
          4,7
         </a>
         ]. As an example:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An eight-week randomized trial compared
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         (300 or 600 mg per day) with placebo for treating bipolar major depression [
         <a href="#rid22">
          22
         </a>
         ]. In the subgroup with rapid cycling (n = 108), response (improvement from baseline on the depression rating scale ≥ 50 percent) occurred in significantly more patients who received quetiapine than placebo (66 versus 29 percent) [
         <a href="#rid15">
          15,17
         </a>
         ]. This was consistent with the finding that each dose of quetiapine was superior to placebo in the total sample [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An eight-week randomized trial compared
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         extended release (300 mg per day) with placebo for treating bipolar major depression [
         <a href="#rid18">
          18
         </a>
         ]. In the subgroup with rapid cycling (n = 74), improvement was greater with quetiapine than placebo. This was consistent with the finding that quetiapine was superior in patients without rapid cycling (n = 196).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A one-year, open-label, randomized study compared
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         (mean dose 465 mg per day) with
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         (mean dose 1340 mg per day) in 38 rapid cycling patients who were euthymic or primarily suffering from depressive symptoms at baseline [
         <a href="#rid25">
          25
         </a>
         ]. Fewer days with moderate to severe depressive symptoms occurred in patients who received quetiapine than in patients who received valproate (12 versus 28 percent of days).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H92692348">
         <span class="h2">
          Resistant patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many rapid cycling bipolar patients with major depression do not respond to
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         [
         <a href="#rid15">
          15,17
         </a>
         ]. For these resistant patients, we suggest sequential treatment with
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and the combination of
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         and
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         . To switch drugs, quetiapine is tapered and discontinued over one to two weeks at the same time that another medication is started and titrated up. We generally taper quetiapine by 50 to 200 mg per day, every one to two days.
        </p>
        <p>
         The following drugs are listed in order of preference, based upon how often each drug has been studied and how well it worked. For resistant rapid cycling bipolar patients with major depression who do not respond to one second-line drug, or do not tolerate the drug, we suggest tapering and discontinuing the failed medication over two or more weeks at the same time that another second-line medication is started and titrated up. The failed medication is generally tapered by the same amount for each dose decrease. As an example,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         200 mg per day is decreased by 50 mg per day, every two to three days.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lamotrigine
         </strong>
         – The initial dose of
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         is 25 mg per day for weeks one and two. For weeks three and four, the dose is increased to 50 mg per day, taken in two divided doses (an extended release formulation is available for once a day dosing). The dose can then be titrated up by 25 to 50 mg per day, one week at a time for each increase. This slow titration reduces the risk of life-threatening skin rash, such as Stevens-Johnson syndrome. The target dose ranges from 50 to 300 mg per day [
         <a href="#rid26">
          26
         </a>
         ]. The side effects and pharmacology of lamotrigine are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">
          "Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Lamotrigine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence for the efficacy of
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         in treating rapid cycling bipolar patients with major depression includes the following studies:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 26-week randomized trial compared
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         (mean dose 288 mg per day) with placebo in 177 rapid cycling bipolar patients who were clinically stable for two weeks [
         <a href="#rid27">
          27
         </a>
         ]. Relapse occurred in significantly fewer patients who received lamotrigine than placebo (59 versus 74 percent). In addition, discontinuation of treatment due to adverse side effects was identical for lamotrigine and placebo (two percent of each group).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A randomized, crossover trial compared
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         (mean daily dose 274 mg per day) with placebo in 31 patients with treatment-resistant mood disorders (74 percent had rapid cycling bipolar disorder) [
         <a href="#rid28">
          28
         </a>
         ]. In the total sample, response occurred in significantly more patients who received lamotrigine than placebo (52 versus 23 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 16-week, open-label, randomized trial (outcome assessed by blinded raters) compared
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         (median dose 250 mg per day) with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         (median serum concentration 0.8 mmol/L) in patients with bipolar major depression [
         <a href="#rid29">
          29
         </a>
         ]. In the subgroup with rapid cycling (n = 68), significant improvement from baseline occurred with each drug, with no significant difference between the two medications; this was consistent with the finding that improvement with each drug was comparable in the total sample.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lithium
         </strong>
         – The dose, side effects, and pharmacology of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , as well as the use of serum levels, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">
          "Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence for the benefit of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         in treating depressed, rapid cycling patients includes the following studies:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         As discussed above, a trial found that improvement of rapid cycling bipolar major depression was comparable for
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         and
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A pooled analysis of three observational studies found that in 172 rapid cycling bipolar patients who were treated with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , recurrent mood episodes did not occur in 34 percent [
         <a href="#rid30">
          30
         </a>
         ]. In a separate pooled analysis of three observational studies with 90 rapid cycling patients who received lithium, the frequency, intensity, and duration of mood episodes decreased by 50 percent or more in 59 percent of patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 12-week randomized trial compared
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         with
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         for treatment of bipolar depression, and the group of patients assigned to lithium included patients who were rapid cyclers (n = 28) and patients who were non-rapid cyclers (n = 36) [
         <a href="#rid31">
          31
         </a>
         ]. Response (reduction of baseline symptoms ≥50 percent) to lithium for rapid cyclers and non-rapid cyclers was comparable (39 and 31 percent of patients).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Olanzapine
         </strong>
         <strong>
          plus
         </strong>
         <strong>
          fluoxetine
         </strong>
         – For patients who do not respond to sequential trials of
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , we suggest
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         plus
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         [
         <a href="#rid15">
          15,32
         </a>
         ]. However, it is reasonable to use a different second-generation antipsychotic such as
         <a class="drug drug_general" data-topicid="16085" href="/z/d/drug information/16085.html" rel="external">
          lurasidone
         </a>
         or quetiapine, and/or to use a different selective serotonin reuptake inhibitor such as
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         ,
         <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">
          escitalopram
         </a>
         , or
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The initial dose of
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         is generally 5 mg per day taken once daily, and the usual target dose range is 5 to 20 mg per day. Olanzapine is increased by 5 mg per day, every one to seven days, depending upon the intensity of specific symptoms, intervening side effects, and response to treatment. As an example, persistent insomnia should prompt a dose increase. The side effects and pharmacology of olanzapine are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The initial dose of
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         is usually 20 mg per day taken once daily, and the target dose range is generally 20 to 60 mg per day. For patients who do not respond to 20 mg per day within two to four weeks, the dose is increased by 10 to 20 mg per day, depending on how well the medication is tolerated. Patients who remain unresponsive to treatment should receive additional increases of 10 to 20 mg per day every two to four weeks as tolerated, to an effective dose within the target dose range. We generally taper and discontinue fluoxetine over one to two weeks soon after the depressive syndrome has resolved (eg, within two to three months). Longer treatment may be associated with poorer outcomes [
         <a href="#rid12">
          12
         </a>
         ]. Fluoxetine is decreased by 10 mg per day, every one to two days. The side effects and pharmacology of fluoxetine are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence for the efficacy of
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         plus
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         includes an eight-week randomized trial that compared olanzapine (mean dose 7 mg per day) plus fluoxetine (mean dose 40 mg per day) with placebo in patients with bipolar major depression [
         <a href="#rid32">
          32
         </a>
         ]. In the subgroup with rapid cycling (n = 164), response (improvement from baseline on the depression rating scale ≥50 percent) occurred in more patients who received the combination than placebo (78 versus 39 percent) [
         <a href="#rid15">
          15,32
         </a>
         ]. This was consistent with results in the total sample that found the combination was superior to placebo. In addition, discontinuation of treatment due to adverse side effects in the rapid cycling subgroup was comparable for patients who received the combination or placebo (5 and 3 percent), as was switching from major depression to mania or hypomania (10 versus 4 percent of patients) [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some authorities avoid antidepressants in rapid cycling bipolar patients with major depression [
         <a href="#rid33">
          33,34
         </a>
         ], because observational studies suggest that antidepressants may exacerbate rapid cycling [
         <a href="#rid8">
          8
         </a>
         ]. However, other observational studies [
         <a href="#rid30">
          30,35,36
         </a>
         ] and randomized trials [
         <a href="#rid31">
          31
         </a>
         ] have failed to find this association. The possible role of antidepressants in the pathogenesis of rapid cycling is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15249.html" rel="external">
          "Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Antidepressants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H92692355">
         <span class="h2">
          Refractory patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon several studies, rapid cycling bipolar patients with major depression frequently do not respond to pharmacotherapy [
         <a href="#rid16">
          16,27,29,37-39
         </a>
         ]. For refractory patients whose depression does not respond to trials of
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and the combination of
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         and
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         , we suggest ECT.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Electroconvulsive therapy (ECT)
         </strong>
         – ECT is generally safe and there are no absolute contraindications, even in patients whose general medical status is compromised [
         <a href="#rid40">
          40
         </a>
         ]. However, safety concerns regarding ECT necessitate preprocedure medical consultation. Adverse effects include cardiopulmonary events, aspiration pneumonia, fractures, dental and tongue injuries, headache, nausea, and cognitive impairment. Medical consultation prior to ECT is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4817.html" rel="external">
          "Medical evaluation for electroconvulsive therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Electrode placement and other aspects of ECT technique for treating rapid cycling bipolar patients with major depression have not been standardized. Thus, ECT is typically administered with the same technique used for other indications and is generally given three times per week on alternating days. Most patients regardless of indication remit with 6 to 12 treatments, but some patients may require 20 or more. Additional information about ECT is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">
          "Overview of electroconvulsive therapy (ECT) for adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">
          "Technique for performing electroconvulsive therapy (ECT) in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence for the efficacy of ECT in treating rapid cycling bipolar patients with major depression includes studies that have found ECT is beneficial for the general population of patients with bipolar depression, who were not selected for rapid cycling. (See
         <a class="medical medical_review" href="/z/d/html/14659.html" rel="external">
          "Bipolar disorder in adults: Indications for and efficacy of electroconvulsive therapy", section on 'Bipolar major depression'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other evidence includes the following studies [
         <a href="#rid41">
          41-44
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A prospective observational study followed 43 patients with rapid cycling bipolar disorder who received ECT; the mood episode resolved and there were no recurrences for at least one year in 26 percent, and temporary improvement occurred in the remaining patients [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a retrospective study, 14 rapid cycling bipolar patients with major depression received ECT (mean number of treatments 23, mean duration of treatment 21 months) [
         <a href="#rid44">
          44
         </a>
         ]. Rapid cycling resolved in every patient and the mean number of mood episodes per year decreased from six to one. However, another retrospective study found that among 24 patients with rapid cycling bipolar disorder who were treated with ECT, none remitted [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Second-generation antipsychotic
         </strong>
         – For rapid cycling bipolar patients with refractory major depression who decline or do not have access to ECT, a reasonable alternative is an adjunctive second-generation antipsychotic other than
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , which we suggest as first-line treatment. (See
         <a class="local">
          'First line medication'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence that supports using a second generation antipsychotic for acute major depression in rapid cycling bipolar disorder includes a prospective observational study of 10 patients who were treated with adjunctive
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         (2 to 6 mg per day) for at least six months; mean depression rating scale scores decreased significantly from baseline [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, second-generation antipsychotic monotherapy does not appear to be useful. An eight-week randomized trial compared
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         monotherapy with placebo in bipolar patients with major depression [
         <a href="#rid32">
          32
         </a>
         ]; in the subgroup with rapid cycling (n = 261), response (improvement from baseline on the depression rating scale ≥50 percent) was comparable for olanzapine and placebo [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Levothyroxine
         </strong>
         <strong>
          (T4)
         </strong>
         – For rapid cycling bipolar patients with refractory major depression who decline or do not have access to ECT, and do not respond to treatment with a second-generation antipsychotic, a reasonable alternative is adjunctive
         <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">
          levothyroxine
         </a>
         (T4), but not triiodothyronine (T3) [
         <a href="#rid47">
          47,48
         </a>
         ]. Use of T4 for rapid cycling patients is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16847.html" rel="external">
          "Rapid cycling bipolar disorder in adults: Treatment of mania and hypomania", section on 'Refractory patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clozapine
         </strong>
         <strong>
         </strong>
         – Although
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         is primarily effective for the treatment of manic episodes in rapid as well as non-rapid cycling bipolar disorder, clozapine may also improve bipolar depression in rapid cycling. A retrospective study identified 13 patients with rapid cycling bipolar disorder who received clozapine (mean dose 180 mg/day, range 25 to 600 mg/day) as add-on therapy or monotherapy [
         <a href="#rid49">
          49
         </a>
         ]. Outcomes during the year before clozapine treatment were compared with the year after clozapine was started. Clozapine was associated with fewer depressive episodes, manic episodes, hospitalizations, and suicide attempts.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H92692362">
         <span class="h1">
          ADJUNCTIVE PSYCHOTHERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Augmenting pharmacotherapy with psychotherapy can help all patients with bipolar disorder, including those with rapid cycling bipolar major depression. We suggest psychoeducation (which teaches patients about the clinical features, treatment, and prognosis of rapid cycling bipolar disorder), based upon the demonstrated efficacy of adjunctive psychoeducation in a meta-analysis of six randomized trials for the general treatment of bipolar disorder [
         <a href="#rid50">
          50
         </a>
         ]. Effective alternatives include cognitive-behavioral therapy (CBT), family therapy, and interpersonal social rhythm therapy. Adjunctive psychotherapy for treating bipolar disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment", section on 'Choosing adjunctive psychotherapy'
         </a>
         .)
        </p>
        <p>
         In a prospective observational study, 10 depressed or euthymic bipolar patients with rapid cycling were treated with 20 sessions of CBT that included psychoeducation, cognitive restructuring of depressive and manic thoughts (eg, “No one loves me” or “I can afford to buy everything”), and skills for managing mood shifts and comorbid psychiatric disorders [
         <a href="#rid51">
          51
         </a>
         ]. Symptomatic improvement occurred in the six patients who completed the study.
        </p>
        <p class="headingAnchor" id="H4223989894">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115361.html" rel="external">
          "Society guideline links: Bipolar disorder"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13496395">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (See
         <a class="medical medical_basics" href="/z/d/html/15348.html" rel="external">
          "Patient education: Bipolar disorder (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16338.html" rel="external">
          "Patient education: Coping with high drug prices (The Basics)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (See
         <a class="medical medical_patient" href="/z/d/html/4869.html" rel="external">
          "Patient education: Bipolar disorder (Beyond the Basics)"
         </a>
         and
         <a class="medical medical_patient" href="/z/d/html/16279.html" rel="external">
          "Patient education: Coping with high prescription drug prices in the United States (Beyond the Basics)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These educational materials can be used as part of psychoeducational psychotherapy. (See
         <a class="medical medical_review" href="/z/d/html/14666.html" rel="external">
          "Bipolar disorder in adults: Psychoeducation and other adjunctive maintenance psychotherapies", section on 'Group psychoeducation'
         </a>
         .)
        </p>
        <p>
         The National Institute of Mental Health also has educational material explaining the symptoms, course of illness, and treatment of bipolar disorder in a booklet entitled "Bipolar Disorder," which is available online at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nimh.nih.gov%2Fhealth%2Fpublications%2Fbipolar-disorder&amp;token=c9TXCEotcdMcarRyXBEnhwgIEx3THC4PwSF2z%2FRKFh%2B8HmGSkeqm5bDBx4bOcfNh0qAPwOVFAtZ6twY6hM0vtq8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=16890" target="_blank">
          the website
         </a>
         or through a toll-free number, 866-615-6464. The web site also provides references, summaries of study results in language intended for the lay public, and information about clinical trials currently recruiting patients.
        </p>
        <p>
         More comprehensive information is provided in many books written for patients and family members, including The Bipolar Disorder Survival Guide: What You and Your Family Need to Know, Third Edition, written by David J. Miklowitz, PhD (published by The Guilford Press, 2019); An Unquiet Mind: A Memoir of Moods and Madness, written by Kay Jamison, PhD (published by Random House, 1995); and Treatment of Bipolar Illness: A Casebook for Clinicians and Patients, by RM Post, MD, and GS Leverich, LCSW (published by Norton Press, 2008).
        </p>
        <p>
         The Depression and Bipolar Support Alliance (accessible at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.dbsalliance.org%2F&amp;token=ZAuWdG5s4GIvjFnkWRP6rC6dBWU8%2FMZEcwGeeAm5c58EpMgcvhu2s4%2FQc68YQejm&amp;TOPIC_ID=16890" target="_blank">
          the website
         </a>
         or 800-826-3632) is a national organization that educates members about bipolar disorder and how to cope with it. Other functions include increasing public awareness of the illness and advocating for more research and services. The organization is administered and maintained by patients and family members, and has local chapters.
        </p>
        <p>
         The National Alliance on Mental Illness (accessible at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nami.org%2FHome&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F8kABYN690CzsdrTBuRq2QekIBbQQeqX70Vmx%2B0z8d0m&amp;TOPIC_ID=16890" target="_blank">
          the website
         </a>
         or 800-950-6264) is a similarly structured organization devoted to education, support, and advocacy for patients with any mental illness. Bipolar disorder is one of their priorities.
        </p>
        <p class="headingAnchor" id="H92693814">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bipolar disorder is characterized by episodes of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 1
         </a>
         ), hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 2
         </a>
         ), and major depression  (
         <a class="graphic graphic_table graphicRef91398" href="/z/d/graphic/91398.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Definition of rapid cycling bipolar disorder'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/86602.html" rel="external">
          "Bipolar disorder in adults: Assessment and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid cycling bipolar disorder is diagnosed in patients with four or more mood episodes during the past 12 months. Although the symptoms that occur as part of a rapid cycling pattern are no different from symptoms that occur as part of a non-rapid cycling pattern, rapid cycling episodes are typically of shorter duration. Separate episodes are demarcated from each other either by a switch from one pole to the other (eg, major depression to mania), or by full or partial remission for at least two months. (See
         <a class="local">
          'Definition of rapid cycling bipolar disorder'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/15249.html" rel="external">
          "Rapid cycling bipolar disorder: Epidemiology, pathogenesis, clinical features, and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Remission of rapid cycling mood episodes often occurs as a result of the course of illness, rather than treatment. Thus, the primary goal of treatment is to prevent further episodes. (See
         <a class="local">
          'General principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For rapid cycling bipolar patients with major depression, we suggest initial treatment with
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         rather than other drugs (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'First line medication'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For resistant rapid cycling bipolar patients with major depression that does not respond to
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         , we suggest sequential treatment with
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and the combination of
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         and
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         , rather than other medications (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Resistant patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For refractory rapid cycling bipolar patients with major depression that does not respond to trials of
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , and the combination of
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         and
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         , we suggest electroconvulsive therapy (ECT) rather than additional pharmacotherapy trials (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Refractory patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For depressed rapid cycling bipolar patients, we suggest augmenting pharmacotherapy with psychotherapy rather than using pharmacotherapy alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We generally use psychoeducation; however, cognitive-behavioral therapy, family therapy, and interpersonal social rhythm therapy are reasonable alternatives. (See
         <a class="local">
          'Adjunctive psychotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, Second Edition, Oxford University Press, Oxford 2007.
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunner DL, Fieve RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strawbridge R, Kurana S, Kerr-Gaffney J, et al. A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder. Acta Psychiatr Scand 2022; 146:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tondo L, Hennen J, Baldessarini RJ. Rapid-cycling bipolar disorder: effects of long-term treatments. Acta Psychiatr Scand 2003; 108:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fountoulakis KN, Tohen M, Zarate CA Jr. Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses. Eur Neuropsychopharmacol 2022; 54:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roosen L, Sienaert P. Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review. J Affect Disord 2022; 311:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneck CD, Miklowitz DJ, Miyahara S, et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry 2008; 165:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013; 170:1249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015; 49:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Mallakh RS, Vöhringer PA, Ostacher MM, et al. Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial. J Affect Disord 2015; 184:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, Beaulieu S, Dunner DL, et al. Rapid cycling bipolar disorder--diagnostic concepts. Bipolar Disord 2008; 10:153.
          </a>
         </li>
         <li class="breakAll">
          Kupka RW, Frye MA. Diagnosis and treatment of rapid cycling bipolar disorder. In: Bipolar Disorder. A clinician’s guide to biological treatments, 2nd Ed, Yatham L, Kusumakar V (Eds), Brunner-Routledge, 2009.
         </li>
         <li class="breakAll">
          Ketter TA, Wang PW. Management of rapid-cycling bipolar disorders. In: Handbook of Diagnosis and Treatment of Bipolar Disorders, Ketter TA (Ed), American Psychiatric Publishing, Inc, Washington, DC 2010. p.331.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneck CD. Treatment of rapid-cycling bipolar disorder. J Clin Psychiatry 2006; 67 Suppl 11:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vieta E, Calabrese JR, Goikolea JM, et al. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007; 9:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suppes T, Datto C, Minkwitz M, et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010; 121:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young AH, McElroy SL, Bauer M, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162:1351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry 2011; 72:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nivoli AM, Colom F, Murru A, et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 2011; 129:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langosch JM, Drieling T, Biedermann NC, et al. Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate. J Clin Psychopharmacol 2008; 28:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suppes T, Marangell LB, Bernstein IH, et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord 2008; 111:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kupka RW, Luckenbaugh DA, Post RM, et al. Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry 2003; 64:1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lorenzo-Luaces L, Amsterdam JD, Soeller I, DeRubeis RJ. Rapid versus non-rapid cycling bipolar II depression: response to venlafaxine and lithium and hypomanic risk. Acta Psychiatr Scand 2016; 133:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koukopoulos A, Sani G, Koukopoulos AE, et al. Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients. J Affect Disord 2003; 73:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghaemi SN. Treatment of rapid-cycling bipolar disorder: are antidepressants mood destabilizers? Am J Psychiatry 2008; 165:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coryell W. Rapid cycling bipolar disorder: clinical characteristics and treatment options. CNS Drugs 2005; 19:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162:2152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kemp DE, Gao K, Ganocy SJ, et al. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence. J Clin Psychiatry 2009; 70:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calabrese JR, Shelton MD, Bowden CL, et al. Bipolar rapid cycling: focus on depression as its hallmark. J Clin Psychiatry 2001; 62 Suppl 14:34.
          </a>
         </li>
         <li class="breakAll">
          McDonald WM, Meeks TW, Carpenter LL, et al. Electroconvulsive therapy and other neuromodulation therapies. In: The American Psychiatric Association Publishing Textbook of Psychiatry, Fifth Edition, Schatzberg AF, Nemeroff CB (Eds), American Psychiatric Association Publishing, Arlington, VA 2017. p.1105.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanelle JM, Loo H, Galinowski A, et al. Maintenance ECT in intractable manic-depressive disorders. Convuls Ther 1994; 10:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kho KH. Treatment of rapid cycling bipolar disorder in the acute and maintenance phase with ECT. J ECT 2002; 18:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berman E, Wolpert EA. Intractable manic-depressive psychosis with rapid cycling in an 18-year-old woman successfully treated with electroconvulsive therapy. J Nerv Ment Dis 1987; 175:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minnai GP, Salis PG, Oppo R, et al. Effectiveness of maintenance electroconvulsive therapy in rapid-cycling bipolar disorder. J ECT 2011; 27:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry 1988; 145:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vieta E, Gasto C, Colom F, et al. Treatment of refractory rapid cycling bipolar disorder with risperidone. J Clin Psychopharmacol 1998; 18:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, Adli M, Bschor T, et al.. Clinical applications of levothyroxine in refractory mood disorders. Clinical Approaches in Bipolar Disorders 2003; 2:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walshaw PD, Gyulai L, Bauer M, et al. Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: A double-blind placebo-controlled trial of levothyroxine (L-T4 ) and triiodothyronine (T3 ). Bipolar Disord 2018; 20:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kılınçel O, Kılınçel Ş, Gündüz C, et al. The Role of Clozapine as a Mood Regulator in the Treatment of Rapid Cycling Bipolar Affective Disorder. Turk Psikiyatri Derg 2019; 30:268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morriss RK, Faizal MA, Jones AP, et al. Interventions for helping people recognise early signs of recurrence in bipolar disorder. Cochrane Database Syst Rev 2007; :CD004854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reilly-Harrington NA, Deckersbach T, Knauz R, et al. Cognitive behavioral therapy for rapid-cycling bipolar disorder: a pilot study. J Psychiatr Pract 2007; 13:291.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16890 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression, Second Edition, Oxford University Press, Oxford 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4589148" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical factors in lithium carbonate prophylaxis failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35778967" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12807371" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Rapid-cycling bipolar disorder: effects of long-term treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34980362" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35545157" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18198271" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24030475" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29536616" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26643054" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26142612" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18199234" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Rapid cycling bipolar disorder--diagnostic concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18199234" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Rapid cycling bipolar disorder--diagnostic concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18199234" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Rapid cycling bipolar disorder--diagnostic concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17029493" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Treatment of rapid-cycling bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17547587" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19903574" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17110817" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20122369" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20122366" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15994719" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20816033" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Pharmacotherapy for the treatment of acute bipolar II depression: current evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20538341" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : New treatment guidelines for acute bipolar depression: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18794653" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15888514" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11105737" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11106131" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18358540" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14728111" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26803764" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Rapid versus non-rapid cycling bipolar II depression: response to venlafaxine and lithium and hypomanic risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14609883" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12507740" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18316425" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Treatment of rapid-cycling bipolar disorder: are antidepressants mood destabilizers?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15984894" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Rapid cycling bipolar disorder: clinical characteristics and treatment options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19329543" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16263857" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19192457" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and Co-occurring substance abuse or dependence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11469674" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Bipolar rapid cycling: focus on depression as its hallmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11469674" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Bipolar rapid cycling: focus on depression as its hallmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7834256" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Maintenance ECT in intractable manic-depressive disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12394535" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Treatment of rapid cycling bipolar disorder in the acute and maintenance phase with ECT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3559536" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Intractable manic-depressive psychosis with rapid cycling in an 18-year-old woman successfully treated with electroconvulsive therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20559148" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Effectiveness of maintenance electroconvulsive therapy in rapid-cycling bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3341463" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9555604" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Treatment of refractory rapid cycling bipolar disorder with risperidone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Clinical applications of levothyroxine in refractory mood disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29869405" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: A double-blind placebo-controlled trial of levothyroxine (L-T4 ) and triiodothyronine (T3 ).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32594488" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The Role of Clozapine as a Mood Regulator in the Treatment of Rapid Cycling Bipolar Affective Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17253526" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Interventions for helping people recognise early signs of recurrence in bipolar disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17890977" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Cognitive behavioral therapy for rapid-cycling bipolar disorder: a pilot study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
